pharmaceuticals

Eli Lilly Logo

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share ...
Read Full Story »
Prescription drugs

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

Johnson & Johnson (NYSE: JNJ) has been working on its pipeline for a while, and plans on continuing to do so. In an effort to strengthen its portfolio, this pharmaceutical ...
Read Full Story »
biotech

Is This the End of the Growth Phase for Intercept?

Investors are not too happy with Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) after it released the terms for its most recent clinical trial. Over the course of 2015, shares have nearly ...
Read Full Story »
Prescription drugs

The 5 Winners and Losers From ASCO Presentations

With the American Society of Clinical Oncology (ASCO) annual meeting just two weeks away, investors, doctors and cancer patients are anxiously awaiting some of the key presentations and abstracts that ...
Read Full Story »
Pentagon, defense

AcelRX Takes Flight With New Department of Defense Contract

A number of pharmaceutical companies are working toward a better solution to manage pain. AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) is one of them, but what separates it from the pack ...
Read Full Story »
research

Analyst Issues 5 Potential Biotech Buyout Candidates

We have said it before, and we will stress it once again, one of the best ways for big pharmaceuticals and biotech companies to grow is through acquisitions. In a ...
Read Full Story »
153576724

Are Problems at Orexigen Still Just Getting Started?

Orexigen Therapeutics Inc. (NASDAQ: OREX) had to bite the bullet Tuesday when it announced that it would be terminating its cardiovascular outcomes study of the obesity drug Contrave. However, things ...
Read Full Story »
Pills

Why the DepoMed Drop Is a Gross Overreaction

Sometimes, or lots of times, investors and markets take things a little too far. For instance, a stock might overreact, to the upside or downside, based on too much optimism ...
Read Full Story »
thumbs up

Could This Speculative Biotech More Than Triple?

Pharma companies are generally riskier than most normal companies, but with this risk comes a huge reward, like the one that Oppenheimer sees in Tokai Pharmaceuticals Inc. (NASDAQ: TKAI). The ...
Read Full Story »
DNA

Why This Study May Have Saved Pain Therapeutics

Both biotech and pharmaceutical companies have a mission to make life better for everyone through the innovation and production of drugs that can save lives. Pain Therapeutics Inc. (NASDAQ: PTIE) ...
Read Full Story »
Prescription drugs

Short Sellers Keep Strong Bets Against Big Pharma

The short interest data has been released for the April 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
145922793

GSK Takes Aim at AIDS/HIV Cure, Funding Company With University of North Carolina at Chapel Hill

Any time that you hear about new drugs and medical treatments, they tend to be around ongoing treatments rather than cures. And when it comes to AIDS and HIV, the ...
Read Full Story »
tesla-model-s-blue

4 Top Jefferies Growth Stock Calls for This Week

With a burst on Friday, the markets fought back into the green for the year, albeit barely. Through the first four and a half months of the year, the S&P ...
Read Full Story »
Biotechnology word cloud

4 Speculative Biotechs With Huge Analyst Targets

Investors have been in love with the speculative biotech sector for years now. If there is one group of stocks that can produce returns of 100%, 200% or even ten-baggers, ...
Read Full Story »
biotech

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

There should be no surprise to biotech investors that the mergers and acquisition (M&A) market and chatter are heating up. The huge buy of Synageva Biopharma Corp. (NASDAQ: GEVA) by ...
Read Full Story »